ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Conditions: Pancreatic Ductal Carcinoma Interventions: Drug: ProAgio Dose Levels (DL) 1,2,3,4; Drug: Gemcitabine, nab paclitaxel Sponsors: ProDa BioTech, LLC; University of Alabama at Birmingham; Georgia State University Not yet recruiting

https://clinicaltrials.gov/study/NCT06182072

Source: ClinicalTrials.gov - December 25, 2023 Category: Research Source Type: clinical trials